A clinical study to evaluate the efficacy of ceritinib in combination with nivolumab in patients with ALK positive lung cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510824-38-00

Acronym

CLDK378A2120C

Enrollment

Registered

2024-04-09

Start date

2015-05-27

Completion date

Unknown

Last updated

2025-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026